- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07570940
A Study Of Stellate Ganglion Blockade With Liposomal Bupivacaine In Preventing Atrial Fibrillation After Isolated Coronary Artery Bypass Grafting Surgery
Effectiveness Of Liposomal Bupivacaine Stellate Ganglion Blockade In Preventing Atrial Fibrillation After Isolated Coronary Artery Bypass Grafting Surgery: A Randomized Placebo-Controlled Trial
The purpose of this study is assess the incidence of postoperative atrial fibrillation (POAF) within one week of surgery in patients who receive pre-surgical stellate ganglion blockade with liposomal bupivacaine, compared to those receiving a saline placebo, using continuous electrocardiographic monitoring via wearable ECG devices.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 4
Kontakter och platser
Studiekontakt
- Namn: Anesthesia Clinical Research Unit (ACRU) Study Team
- Telefonnummer: 866-265-9263
- E-post: ripollsanz.juan@mayo.edu
Studieorter
-
-
Minnesota
-
Rochester, Minnesota, Förenta staterna, 55905
- Rekrytering
- Mayo Clinic in Rochester
-
Kontakt:
- ACRU Study Team
- Telefonnummer: 866-265-9263
-
Huvudutredare:
- Juan G. Ripoll Sanz, MD
-
Underutredare:
- Erica Wittwer, MD,PhD
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Adults aged ≥40 years scheduled to undergo isolated coronary artery bypass grafting will be eligible. Robotic CABG procedures are allowed.
- Cases will also remain eligible if, after the initial surgical listing, additional procedures-such as valvular interventions or septal myectomy-are performed, OR if CABG is listed as the primary intervention with other procedures noted as possible additional interventions.
- Cases will remain eligible if left atrial appendage ligation is concomitantly listed with the CABG.
Exclusion criteria:
- History of Permanent atrial fibrillation (paroxysmal, persistent or permanent),
- Mechanical circulatory support implant or explant
- Heart and/or lung transplant patients
- Active infection/sepsis
- Pre-operative anti-arrhythmic use (aside from beta-blockers).
- MAZE procedures, pulmonary vein isolation or cryotherapy will exclude patients if concomitantly listed with the CABG.
- Participant has a known allergy to adhesives or hydrogels.
- Participant has a visible skin injury or broken skin at the location for study device placement.
- Participant does not have the competency to wear the device for the prescribed patching period.
- Participant has a neuro-stimulator, as it may disrupt the quality of ECG data.
- Participants who are pregnant. In accordance with Mayo Clinic's standard cardiac surgery protocol, all women of childbearing potential undergo routine preoperative pregnancy testing. Pregnancy status will therefore be confirmed prior to enrollment. Any participant with a positive pregnancy test will be deemed ineligible and will not be enrolled in the study.
- Participants who lack the capacity to provide informed consent will not be approached or enrolled in this study.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Stellate ganglion block using liposomal bupivacaine
10 mL of liposomal bupivacaine 133 mg (133 mg/10 ml or 1.33%) |
Patients undergoing isolated coronary artery bypass grafting will receive a stellate ganglion block using liposomal bupivacaine prior to surgery |
|
Placebo-jämförare: Sham block using saline placebo
10 mL of saline placebo injected in the plane of the right stellate ganglion |
Patients undergoing isolated coronary artery bypass grafting will receive a saline placebo injection to the stellate ganglion prior to surgery |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Incidence of new-onset postoperative atrial fibrillation (POAF) within one week of isolated coronary artery bypass grafting (CABG) surgery
Tidsram: 1 week
|
Total number of patients to experience postoperative atrial fibrillation within one week of CABG surgery. |
1 week
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Total duration of postoperative atrial fibrillation (POAF) episodes within the first postoperative week
Tidsram: 1 week
|
Duration of postoperative atrial fibrillation episodes will assessed via continuous ECG monitoring and reported in minutes |
1 week
|
|
Number of patients with successful stellate ganglion blockade
Tidsram: 1 week
|
Success rate of the stellate ganglion blockade is defined as a ≥1.0°C increase in ipsilateral hand skin temperature from baseline and/or a reduction in skin sympathetic nerve activity (SKNA) as measured by noninvasive surface recordings pre- and post-block. |
1 week
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Juan G. Ripoll Sanz, MD, Mayo Clinic
Publikationer och användbara länkar
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 25-009333
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .